MIT scientists have created a method to “paint” GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects with smaller doses. Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based drugs used to treat diabetes and support weight loss. However, limited availability and high costs have made it challenging for many patients to begin or maintain therapy. [...]from SciTechDaily https://ift.tt/qRE0ICN
